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Open Forum Infectious Diseases
MAJOR ARTICLE

Dan Ilges,1, David J. Ritchie,1,2 Tamara Krekel,1 Elizabeth A. Neuner,1 Nicholas Hampton,3 Marin H. Kollef,4 and Scott Micek1,2
1

Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA, 2Department of Pharmacy Practice, University of Health Sciences and Pharmacy, St. Louis, Missouri, USA, 3Center for
Clinical Excellence, BJC HealthCare, St. Louis, Missouri, USA, 4Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

Background. Hospital-acquired and ventilator-associated pneumonia (HAP/VAP) cause significant mortality. Guidelines recommend empiric broad-spectrum antibiotics followed by de-escalation (DE). This study sought to assess the impact of DE on treatment failure.
Methods. This single-center retrospective cohort study screened all adult patients with a discharge diagnosis code for pneumonia from 2016 to 2019. Patients were enrolled if they met predefined criteria for HAP/VAP ≥48 hours after admission. Date of
pneumonia diagnosis was defined as day 0. Spectrum scores were calculated, and DE was defined as a score reduction on day 3 versus
day 1. Patients with DE were compared to patients with no de-escalation (NDE). The primary outcome was composite treatment
failure, defined as all-cause mortality or readmission for pneumonia within 30 days of diagnosis.
Results. Of 11 860 admissions screened, 1812 unique patient-admissions were included (1102 HAP, 710 VAP). Fewer patients
received DE (876 DE vs 1026 NDE). Groups were well matched at baseline, although more patients receiving DE had respiratory cultures ordered (56.6% vs 50.6%, P = .011). There was no difference in composite treatment failure (35.0% DE vs 33.8% NDE, P = .604).
De-escalation was not associated with treatment failure on multivariable Cox regression analysis (hazard ratio, 1.13; 95% confidence
interval, 0.96–1.33). Patients receiving DE had fewer antibiotic days (median 9 vs 11, P < .0001), episodes of Clostridioides difficile
infection (2.2% vs 3.8%, P = .046), and hospital days (median 20 vs 22 days, P = .006).
Conclusions. De-escalation and NDE resulted in similar rates of 30-day treatment failure; however, DE was associated with
fewer antibiotic days, episodes of C difficile infection, and days of hospitalization.
Keywords. antibiotic de-escalation; hospital-acquired pneumonia; nosocomial pneumonia; spectrum score; ventilatorassociated pneumonia.
Hospital-acquired pneumonia (HAP) is the most common
hospital-acquired infection, accounting for 22% of all nosocomial infections [1]. Mortality rates for HAP and ventilatoracquired pneumonia (VAP) are high, ranging from 20% to
60% [2]. Inappropriate initial antimicrobial therapy is associated with increased mortality in patients with pneumonia,
highlighting the need for initial broad-spectrum therapy [3].
The 2016 Infectious Diseases Society of America and American
Thoracic Society guidelines recommend broad empiric coverage for patients with HAP and VAP, including treatment
for methicillin-resistant Staphylococcus aureus (MRSA) and
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Pseudomonas aeruginosa (PSAR), followed by antibiotic de-escalation (DE) [2].
De-escalation refers to narrowing antimicrobial therapy, including complete cessation of antibiotics, to target likely pathogens while limiting activity against non-pathogenic flora [4].
Risks associated with prolonged and/or unnecessary antibiotic
use are well documented. These include increased development
of antimicrobial resistance, increased antibiotic adverse effects,
and increased risk of Clostridioides difficile infection [4, 5].
Excess use of antibiotics has also been linked to more days in
the intensive care unit (ICU) and a longer duration of hospitalization overall [6].
Defining DE for the purpose of research has proved challenging [7]. For this reason, many studies use qualitative measures, defining DE as the cessation of anti-MRSA coverage,
anti-PSAR coverage, or both [8, 9]. However, these strategies
neglect the full spectrum of activity provided by an antibiotic
regimen, which can have important implications for both the
human microbiome and local resistance patterns [10, 11]. In
recent studies, quantitative methods (ie, spectrum scores) have
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Assessment of Antibiotic De-escalation by Spectrum Score
in Patients With Nosocomial Pneumonia: A Single-Center,
Retrospective Cohort Study

METHODS
Study Design and Patient Population

This study was a retrospective cohort study of patients admitted
to Barnes-Jewish Hospital, a 1300-bed academic medical center
in St. Louis, Missouri, from January 1, 2016 to December 31,
2019. The study was approved by the Washington University institutional review board (IRB no. 2018801189) without the need
to obtain informed consent. All adult admissions coded with an
International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) or International Classification of
Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)
discharge diagnosis code for pneumonia during the study
period of interest were screened for inclusion (Supplementary

Appendix). Patients were enrolled if they met predefined criteria for HAP or VAP, which included the following: (1) index
date of infection onset ≥48 hours after hospital admission for
HAP or ≥48 hours after initiation of mechanical ventilation for
VAP, (2) chest radiograph completed within ± 24 hours of index
pneumonia date, (3) active orders for either anti-MRSA or antiPSAR antibiotics, and (4) at least 1 sign of infection, including
a white blood cell count ≥11 or ≤4 × 109 cells/L, or temperature
≥38 or ≤36°C [8, 16–18]. To further support the diagnosis of
pneumonia, a random sample of patients had their chest radiographs reviewed by an investigator (M. H. K.) blinded to group
allocation, which demonstrated >95% agreement with the presence of radiographic infiltrates that could be consistent with
pneumonia. Only the first eligible admission for a given patient
was included. Patients were excluded if they discharged or died
before day 3 or if they met criteria for pneumonia within 48
hours of hospital admission. The index date of pneumonia diagnosis was defined as day 0 (Figure 1).
All pharmacy-verified intravenous and oral antibiotic orders
of interest were captured for each day of admission. Oral vancomycin, oral sulfamethoxazole/trimethoprim, and intravenous
daptomycin orders were excluded. Spectrum scores were computed using a modified version of the ASI, adopted from Gerber
et al [15] (Supplementary Table 1). Scores were calculated for
antibiotics ordered on day 0 and for each successive day after

Cultures
Chest X-ray
Assessment of composite treatment
failure: all-cause mortality or readmission
for pneumonia

WBC
Temp

∆ Spectrum score

Abx
Admission

Day –1 Day 0

Day 1

Day 2

Index date of
pneumonia diagnosis
11860 admissions screened from 9717
patients with ICD-9/10 discharge
diagnosis codes for pneumonia

1812 patients
included

Group 1: DE 786
445 Patients HAP
341 Patients VAP

Day 3

Day 4

Assessment of DE

Day 8

Day 9

Day 30

Assessment of RE

10048 admissions excluded
7671 did not meet pneumonia criteria
WBC, temperature, or chest X-ray
1619 met pneumonia criteria within 48 hours
529 not on anti-MRSA or anti-PSAR abx on day 1
206 discharged/expired before day 3
23 repeat admissions

Group 2: NDE 1026
657 Patients HAP
369 Patients VAP

Figure 1. Study schematic and flow diagram. Abx, antibiotics; DE, de-escalation; HAP, hospital-acquired pneumonia; ICD, International Classification of Diseases; MRSA,
methicillin-resistant Staphylococcus aureus; NDE, no de-escalation; PSAR, Pseudomonas aeruginosa; RE, re-escalation; Temp, temperature; VAP, ventilator-associated
pneumonia; WBC, white blood cell count.
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been developed that approximate the antimicrobial spectrum of
a given agent, although the methodology for calculating such
scores can become burdensome [12–14]. Gerber et al [15] developed a simple spectrum score, described as an antibiotic
spectrum index (ASI). This method proved to be useful in assessing the impact of a stewardship intervention aimed at reducing the use of broad-spectrum antibiotics in the treatment
of community-acquired pneumonia [15]. The purpose of this
study was to evaluate the impact of DE, defined using a modified version of the ASI, on outcomes of patients with HAP/VAP.

Outcomes

Patients were divided into 2 groups based on whether or not antibiotic DE occurred, which was defined as a reduction in spectrum score on day 3 compared with day 1 [13]. Patients with
no change or an increase in spectrum score on day 3 compared
to day 1 were classified as no de-escalation (NDE). Assessment
of DE on day 3 was chosen to allow time for culture and susceptibility testing and for medical teams to respond to culture
results.
The primary outcome was a composite of all-cause mortality
or readmission for pneumonia within 30 days of pneumonia diagnosis. Secondary outcomes included the individual components of the primary outcome, as well as 14-day mortality, total
hospital length of stay, ICU days, ventilator-free days, new vasopressor initiation, new onset C difficile infection up to 90 days
postadmission, antibiotic days, treatment re-escalation, and development of acute kidney injury (AKI). Antibiotic days were
calculated as the number of days that each patient had study
antibiotics ordered from day 0 to 28. Treatment re-escalation
was defined as an increase in spectrum score on or after day
8 to a value greater than the highest score on days 3 to 7 of

hospitalization. Acute kidney injury was defined using serum
creatinine according to the Kidney Disease—Improving Global
Outcomes guidelines [20]. Baseline serum creatinine was defined as the maximum creatinine value on day 0.
Statistical Analysis

Baseline characteristics are presented using descriptive statistics. Categorical variables were compared using the χ2 test.
Continuous variables were assessed for normality and compared using the Student t test or Mann-Whitney U test, as appropriate. The composite outcome of 30-day all-cause mortality
or readmission for pneumonia was assessed using a log-rank
test and Kaplan-Meier survival curve. To help control for confounding variables, predictors of the primary composite outcome were determined using a multivariable Cox regression
analysis. De-escalation status, characteristics that were statistically significant on bivariate analysis (P < .05), and factors
known to influence mortality were considered for inclusion in
the model. Number of vasopressors (from 0 to 3) and ventilator
status (yes/no) for days 0 through 3 were also included in the
model, because these variables often influence clinical decision
making with regards to antibiotic therapy. Predefined subgroup
analyses were conducted for the primary outcome based on age,
diagnosis, APACHE II score, sepsis diagnosis, and negative respiratory culture status.
We determined that 476 patients would be needed in each
group to detect a 10% difference in the primary composite outcome of 30-day all-cause mortality or readmission for pneumonia, assuming a baseline incidence of 30%, with 90% power
and a 2-sided alpha level of 0.05. Significance was defined as
P < .05. All data were analyzed using IBM SPSS Statistics 25 for
Windows.
RESULTS

A total of 11 860 admissions from 9717 unique patients were
screened for inclusion (Figure 1). Of these, 10 048 admissions
were excluded. The most common reasons for exclusion were
failure to meet pneumonia criteria and meeting pneumonia criteria within 48 hours of admission. The final cohort consisted
of 1812 specific patient-admissions, 786 (43.4%) of which were
identified as DE. The median age was 62 years and 41.3% (749
of 1812) of patients were female. The median time from admission to diagnosis was 5 days, and 88.9% (1610 of 1812) of patients were in the ICU on day 0. A total of 60.8% of patients
(1102 of 1812) had a diagnosis of HAP, 37.2% (410 of 1102)
of which were ventilated, whereas the remaining patients had a
diagnosis of VAP.
Overall, patient groups were well matched on baseline characteristics (Table 1). Patients in the DE group were more likely
to have VAP compared to those in the NDE group (43.4% vs
36.0%; P = .001). Modified APACHE II scores were higher
Spectrum Score-based DE in HAP/VAP • OFID • 3
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the index date of pneumonia diagnosis. When multiple antibiotics were ordered, the spectrum scores of the respective
agents were summed into a composite score. For example, a
patient on vancomycin and cefepime received a score of 12 (7
points for cefepime; 5 for vancomycin). The Acute Physiologic
Assessment and Chronic Health Evaluation (APACHE) II score,
modified to exclude the Glasgow Coma Scale score, was used to
assess baseline severity of illness on admission. The Charlson
comorbidity index (CCI) was calculated using methods previously described [19] to assess comorbidities at baseline. Orders
for immunosuppressive medications were queried during
the index admission and up to 30 days prior (Supplementary
Appendix). Vasopressor orders queried included norepinephrine, vasopressin, and dobutamine. Creatinine clearance was estimated each day by the Cockcroft-Gault formula based on the
highest serum creatinine value available.
Microbiologic data, including respiratory cultures, respiratory viral polymerase chain reaction tests, MRSA nasal culture swabs, and blood cultures, were collected from days –1
to 3 of index pneumonia diagnosis (Figure 1). Respiratory
cultures were classified as sputum-like specimens, which included sputum and tracheal aspirates, and bronchoscopy specimens, which included bronchoalveolar lavage, washings,
and brushings. Respiratory samples identified as positive for a
likely pathogen excluded those with only yeast, fungal structural elements, and/or clinically insignificant flora. Blood cultures identified as positive for a likely pathogen excluded those
with only coagulase-negative Staphylococci. Additional microbiological testing and reporting information is available in the
Supplementary Appendix.

Table 1.

Baseline Characteristics

Characteristic

Total (n = 1812)

DE (n = 786)

NDE (n = 1026)

Age, years

62 [51–71]

62 [51–71]

61 [50–70]

.095

Female

749 (41.3)

317 (40.3)

432 (42.1)

.447

White

1314 (72.5)

556 (70.7)

758 (73.9)

African American

409 (22.6)

194 (24.7)

215 (21.0)

89 (4.9)

36 (4.6)

53 (5.2)

Height, m

1.7 [1.6–1.8]

1.7 [1.6–1.8]

1.7 [1.6–1.8]

Weight, kg

81.2 [67.1–99.8]

80.7 [66.4–99.8]

81.5 [67.2–99.7]

.860

BMI, kg/m2

27 [23–33]

27 [23–33]

27 [23–33]

.634

13 [9–17]

13 [10–17]

12 [9–16]

202 (11.1)

77 (9.8)

125 (12.2)

1610 (88.9)

709 (90.2)

901 (87.8)

4 [2–6]

3 [2–6]

4 [2–6]

.045

Race

Modified APACHE II score

.197

Location Diagnosed
Medical ward
ICU
Charlson comorbidity index

.229

<.001
.110

Comorbid Conditions
Heart failure

776 (42.8)

327 (41.6)

449 (43.8)

.357

Myocardial infarction

426 (23.5)

173 (22.0)

253 (24.7)

.188

Stroke

361 (19.9)

156 (19.8)

205 (20.0)

.944

Chronic obstructive pulmonary disease

334 (18.4)

134 (17.0)

200 (19.5)

.183

Liver disease

263 (14.5)

107 (13.6)

156 (15.2)

.341

Diabetes

495 (27.3)

210 (26.7)

285 (27.8)

.616

Renal disease

607 (33.5)

254 (32.3)

353 (34.4)

.350

Leukemia

198 (10.9)

71 (9.0)

127 (12.4)

.024

Lymphoma

83 (4.6)

41 (5.2)

42 (4.1)

.257

Cystic fibrosis

29 (1.6)

5 (0.6)

24 (2.3)

.004

Transplant Status
Solid organ transplant (non-lung)

40 (2.2)

19 (2.4)

21 (2.0)

.595

Lung transplant

50 (2.8)

18 (2.3)

32 (3.1)

.286

95 (5.2)

35 (4.5)

60 (5.8)

.187

Immunosuppressive medications

Bone marrow transplant

248 (13.7)

84 (10.7)

164 (16.0)

.001

Sepsis

1100 (60.7)

469 (59.7)

631 (61.5)

.429

778/1100 (70.7)

327/469 (69.7)

451/631 (71.5)

.316

Number of vasopressors on day 0, mean ± SD

0.69 ± 0.84

0.66 ± 0.83

0.71 ± 0.85

.225

Lowest MAP on index date, mmHga

75 [64–87]

74 [63–87]

76 [65–87]

.217

<1000 cells/µL

32 (1.8)

12 (1.5)

20 (1.9)

.498

<500 cells/µL

18 (1.0)

8 (1.0)

10 (1.0)

.927

37.0 [36.7–37.5]

37.0 [36.7–37.6]

37.0 [36.7–37.4]

.019

11.5 [7.8–16.8]

11.5 [7.9–16.4]

11.6 [7.7–17.0]

.845

122 (6.7)

57 (7.3)

65 (6.3)

.440

Admission

1.03 [0.75–1.45]

1.03 [0.72–1.46]

1.03 [0.77–1.44]

.446

Index date

0.99 [0.70–1.55]

0.95 [0.69–1.51]

1.02 [0.70–1.57]

.278

Admission

62 [41–84]

61 [40–86]

62 [43–82]

.939

Index date

58 [39–82]

58 [37–85]

58 [39–80]

.814

1102 (60.8)

445 (56.6)

657 (64.0)

.001

410 (37.2)

170 (38.2)

240 (36.5)

.673

710 (39.2)

341 (43.4)

369 (36.0)

.001

5 [3–10] (2–168)

5 [3–10]

5 [3–10]

.271

Septic shock

Neutropenia on day 0

Tmax on index date, mean (SD)a
WBC on index datea
Dialysis
Serum Creatinine, mg/dLb

Creatinine Clearance, mL/minb

Diagnosis
HAP
   Ventilated HAP
VAP
Days from admission to diagnosis (range)

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; DE, de-escalation; HAP, hospital-acquired pneumonia; ICU, intensive care unit; NDE, no
de-escalation; MAP, mean arterial pressure; SD, standard deviation; WBC, white blood cell count.
NOTE: Results shown as no. (%) or median [interquartile range] unless otherwise indicated.
a

Tmax data only available for 1727 patients; WBC available for 1571 patients; MAP available for 1803 patients.

b

Includes only patients without dialysis on admission or renal replacement therapy before day 0: 607 in DE group and 765 in NDE group.
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Other/unknown

P Value

There were 423 patients still in the cohort (did not discharge
or die) on day 27 (Figure 2, Supplementary Table 4). Of these,
243 of 423 (57.4%) remained on antibiotics of interest, with a
median spectrum score of 9. Compared to the overall cohort,
patients remaining on antibiotics on day 27 were numerically
more likely to have leukemia (17.7% vs 10.9%), cystic fibrosis
(2.9% vs 1.6%), coinfection (53.9% vs 34.0%), or receive immunosuppressive medications (21.0% vs 13.7%) (Supplementary
Table 5).
DISCUSSION

In this large study of 1812 patients with HAP and VAP, antibiotic
DE identified using changes in spectrum scores was not associated with 30-day composite treatment failure when compared
to NDE. This lack of association persisted after controlling for
confounding variables on multivariable Cox regression analysis
and remained consistent among prespecified subgroups.
De-escalation is recommended following positive culture
data (ie, narrowing to pathogen-directed therapy) and in clinically stable patients following negative cultures [2]. Despite
these recommendations, DE may not occur. A recent retrospective study found that DE rates ranged from 2% to 35% following
negative cultures in patients with pneumonia among 164 US
hospitals from 2010 to 2015, although DE in this study was defined as cessation of both anti-MRSA and anti-PSAR therapies
[21]. Similar to our study, a recent comprehensive systematic
review and meta-analysis of 9 observational studies comprising
2128 patients with pneumonia in the ICU found that DE was
associated with shorter hospital stay but had no discernable
impact on mortality, although all studies were assessed as
low-quality evidence [22]. Additional studies published after
this meta-analysis have also found similar mortality outcomes
among patients who received DE versus those who did not [13,
23, 24].
One difficulty in interpreting the DE literature is the wide
range of definitions used, many of which are subjective and require chart review [22]. We opted to calculate spectrum scores
using the modified ASI [15] and defined DE as a reduction in
score on day 3 compared to day 1. Bohan et al [13] also used
spectrum scores to define DE in a large retrospective cohort
of veterans hospitalized with healthcare-associated pneumonia. Although the spectrum scoring methodology differed
from ours, DE was similarly defined as a reduction in overall
score. Likewise, there were no differences in clinical outcomes
in patients who received DE versus those who did not [13]. In
keeping both with traditional definitions of DE and antimicrobial stewardship program initiatives, patients in the DE group
in our study had a 65% and 44% reduction in anti-MRSA and
anti-PSAR therapies on day 3, respectively, contrasting starkly
with the relatively unchanged utilization of these agents on day
3 in the NDE group.
Spectrum Score-based DE in HAP/VAP • OFID • 5
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among patients in the DE group (13 DE vs 12 NDE; P < .001),
whereas CCI scores were higher among patients in the NDE
group (3 DE vs 4 NDE; P = .045). Patients in the DE group were
less likely to carry diagnoses of leukemia or cystic fibrosis or
have received immunosuppressive medications in prior 30 days.
There was no difference between groups based on transplant
status, septic shock status, or neutropenia.
The most commonly ordered antibiotics were vancomycin,
cefepime, meropenem, and linezolid (Table 2). The median
spectrum score on day 1 was 14. Spectrum score trends over
time are shown in Figure 2 and Supplementary Figure 1.
Patients receiving DE experienced a 65% and 44% reduction
in anti-MRSA and anti-PSAR therapies by day 3, respectively
(Supplementary Figure 2). Significantly more patients in the
DE group had respiratory bacterial cultures completed compared to those in the NDE group (56.6% vs 50.6%; P = .011).
Accordingly, patients in the DE group were more likely to have
respiratory cultures with a likely bacterial pathogen (50.8% vs
39.3%; P < .001) and/or clinically insignificant flora (19.3%
vs 14.8%) compared to patients in the NDE group. The most
common bacteria isolated were S aureus, P aeruginosa, and
Enterobacter spp at 38.6%, 17.7%, and 9.5%, respectively.
Primary and secondary outcomes are shown in Table 3.
There was no difference between groups in the primary outcome of 30-day composite treatment failure on bivariate
analysis (35.0% DE vs 33.8% NDE; P = .604) or log-rank test
(Supplementary Figure 3). There were also no differences in
the individual components of the composite primary outcome,
in-hospital mortality, 14-day all-cause mortality, readmission
for any indication, or treatment re-escalation. However, patients in the DE group had fewer antibiotic days (median 9 vs
11, P < .0001), episodes of C difficile (2.2% vs 3.8%, P = .046),
and hospital days (median 20 vs 22 days, P = .006). Patients in
the DE group also spent less time in the ICU and on a ventilator compared to patients in the NDE group. In addition, there
were consistent trends towards reduced AKI and initiation of
renal replacement therapy in patients in the DE group compared to those in the NDE group.
Supplementary Table 2 shows the results of the multivariable
Cox regression analysis. After controlling for confounding
variables, including ventilator status and number of vasopressors by day, DE was not found to be a significant predictor of
30-day composite treatment failure (hazard ratio, 1.13; 95%
confidence interval, 0.96–1.33). Statistically significant predictors of the primary outcome included modified APACHE
II score, CCI, HAP status, septic shock, leukemia, and ventilator status on day 3. Attainment of respiratory specimens
positive for a likely pathogen was also a statistically significant
predictor of the primary outcome. The prespecified subgroup
analysis did not identify any differences between groups in
terms of 30-day all-cause mortality or readmission for pneumonia (Supplementary Table 3).

Table 2.

Antibiotic and Culture Data

Characteristic

Total (n = 1812)

DE (n = 786)

NDE (n = 1026)

P Value

Baseline Antibiotics on Day 1
1012 (55.8)

481 (61.2)

531 (51.8)

<.001

Cefepime

951 (52.5)

445 (56.6)

506 (49.3)

.002

Meropenem

616 (34.0)

269 (34.2)

347 (33.8)

.857

Linezolid

468 (25.8)

218 (27.7)

250 (24.4)

.104

Azithromycin

278 (15.3)

164 (20.9)

114 (11.1)

<.001

Piperacillin-tazobactam

112 (6.2)

58 (7.4)

54 (5.3)

.064

Ceftriaxone

91 (5.0)

69 (8.8)

22 (2.1)

<.001

Gentamicin

22 (1.2)

18 (2.3)

4 (0.4)

<.001

Antibiotics on Day 3
Vancomycin

675 (37.3)

143 (18.2)

532 (51.9)

<.001

Cefepime

687 (37.9)

191 (24.3)

496 (48.3)

<.001

Meropenem

601 (33.2)

166 (21.1)

435 (42.4)

<.001

Linezolid

405 (22.4)

83 (10.6)

322 (31.4)

<.001
<.001

Azithromycin

167 (9.2)

44 (5.6)

123 (12.0)

Piperacillin-tazobactam

82 (4.5)

28 (3.6)

54 (5.3)

.084

Ceftriaxone

163 (9.0)

110 (14.0)

53 (5.2)

<.001

Gentamicin

13 (0.7)

3 (0.4)

10 (1.0)

.138

Day 1 (mean ± SD)

2 [2–3]

2 [2–3] (2.57 ± 0.8)

2 [2–2] (2.04 ± 0.7)

<.001

Day 3

2 [1–2]

1 [1–2]

2 [2–3]

<.001

Number of Antibiotics

Anti-MRSA Antibiotic
Day 1

1494 (82.5)

687 (87.4)

807 (78.7)

<.001

Day 3

1090 (60.2)

239 (30.4)

851 (82.9)

<.001

Day 1

1670 (92.2)

729 (92.7)

941 (91.7)

.418

Day 3

1371 (75.7)

408 (51.9)

963 (93.9)

<.001

Antipseudomonal Antibiotic

Spectrum Score
Admission

3 [0–13]

3 [0–13]

5 [0–12]

.766

Day 0

14 [11–16]

14 [11–16]

13 [12–16]

.786

Day 1

14 [12–16]

15 [12–18]

13 [10–15]

<.001

Day 3

12 [7–15]

7 [3–12]

15 [12–16]

<.001

964 (53.2)

445 (56.6)

519 (50.6)

.011

523/964 (54.3)

257/445 (57.8)

266/519 (51.3)

.043

Respiratory Samples Ordered
Positive for likely respiratory pathogen
MRSA Nasal Swab Sent
Negative result

821 (45.3)

368 (46.8)

453 (44.2)

.258

758/821 (92.3)

339/368 (92.1)

419/453 (92.5)

.841
.023

Respiratory Specimen Typea
Sputum-like

631 (65.5)

308 (69.2)

323 (62.2)

BAL

464 (48.1)

207 (46.5)

257 (49.5)

.352

304 (16.8)

152 (19.3)

152 (14.8)

.011
.494

Respiratory clinically insignificant florab
Respiratory virus isolated

118 (12.2)

51 (11.5)

67 (12.9)

Respiratory yeast isolated

220 (22.8)

93 (20.9)

127 (24.5)

.188

Respiratory mold isolated

23 (2.4)

5 (1.1)

18 (3.5)

.017

Respiratory bacteria isolated

430 (44.6)

226 (50.8)

204 (39.3)

<.001

Staphylococcus aureus

166 (38.6)

81 (35.8)

85 (41.7)

.215

Methicillin-susceptible

83 (50.0)

42 (51.9)

41 (48.2)

.641

Methicillin-resistant

83 (50.0)

39 (48.1)

44 (51.8)

.641

Vancomycin-intermediate

2 (1.2)

0

2 (2.4)

.497

Pseudomonas aeruginosa

76 (17.7)

42 (18.6)

34 (16.7)

.603

Enterobacter spp

41 (9.5)

25 (11.1)

16 (7.8)

.256
.117

Escherichia coli

37 (8.6)

24 (10.6)

13 (6.4)

Klebsiella spp

34 (7.9)

16 (7.1)

18 (8.8)

.503

Haemophilus spp

28 (6.5)

14 (6.2)

14 (6.9)

.779

Stenotrophomonas maltophilia

25 (5.8)

10 (4.4)

15 (7.4)

.195

Serratia marcescens

23 (5.3)

14 (6.2)

9 (4.4)

.412

Streptococcus pneumoniae

16 (3.7)

7 (3.1)

9 (4.4)

.472

Acinetobacter spp

12 (2.8)

4 (1.8)

12 (2.8)

.176
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Vancomycin

Table 2.

Continued

Characteristic

Total (n = 1812)

DE (n = 786)

NDE (n = 1026)

P Value

8 (1.9)

5 (2.2)

3 (1.5)

.570

Proteus spp

7 (1.6)

6 (2.7)

1 (0.5)

.077

Streptococcus agalactiae

6 (1.4)

4 (1.8)

2 (1.0)

.486

557 (70.9)

713 (69.5)

Blood Culture Sent

1270 (70.1)

Positive for likely bacterial pathogen

105/1270 (8.3)

42/557 (7.5)

.527

63/713 (8.8)

.405

No respiratory or blood cultures sent day −1 to 3

366 (20.2)

151 (19.2)

215 (21.0)

.359

Coinfection during admission

616 (34.0)

262 (33.3)

354 (34.5)

.602

Abbreviations: BAL, bronchoalveolar lavage; DE, de-escalation; MRSA, methicillin-resistant Staphylococcus aureus; NDE, no de-escalation; SD, standard deviation.
NOTE: Results shown as no. (%) or median [interquartile range] unless otherwise indicated.
a

Sputum-like = sputum, induced-sputum, and tracheal aspirates; BAL = washings and brushings.

b

Clinically insignificant flora is only reported when other bacterial/fungal species are identified and reported in culture.

in the timing of swabs (eg, swabbing on admission vs on suspicion of nosocomial pneumonia). Although these findings underscore the importance of obtaining respiratory samples, there
was also no difference in composite treatment failure in patients
with culture-negative pneumonia (either due to negative cultures or lack of cultures altogether). These data suggest that
DE is safe in both circumstances and should be given strong
consideration by clinicians managing patients with nosocomial
pneumonia regardless of negative respiratory cultures.
The spectrum score-based methodology used in our study
allows for objective, measurable, and reproducible identification of DE. Spectrum scores, such as the modified ASI, may
also prove useful for benchmarking, both internally (for assessment of quality improvement projects) and externally (to compare to other institutions and identify areas of opportunity). For
example, Yarrington et al [25] deployed the ASI to understand
antimicrobial use across space and time within their institution,
noting that utilization of broad-spectrum agents increases overnight and on weekends. Efforts are currently underway at our
institution to incorporate the modified ASI into the electronic
medical record, which would facilitate real-time quantification

A drawback of retrospective research is the inherent selection bias present in treatment groups. For example, clinicians
may not pursue DE in patients assessed as having a poor clinical status. In our study, patients with cystic fibrosis or leukemia
were less likely to be de-escalated, although these represented
small subgroups. However, strong predictors of mortality, such
as septic shock and APACHE II score, were well balanced between treatment groups. Patients in the DE group were also
more likely to have a positive respiratory pathogen obtained,
which was shown to be a significant predictor of 30-day composite treatment failure. After controlling for these and other
clinical parameters, such as ventilator status and number of
vasopressors by day, there was no association between DE and
the primary outcome.
One notable finding in this real-world study is the difference
in respiratory culture data between comparison groups. Patients
who had respiratory cultures ordered between days –1 and 3
were more likely to have a pathogen identified and to receive
DE, regardless of respiratory specimen type. It is interesting to
note that obtaining MRSA nasal culture swabs was not associated with DE; however, this could be due in part to variations
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Median spectrum score DE

Median spectrum score NDE

Number patients DE

Number patients NDE

Median spectrum scores day 0 to 28. DE, de-escalation; ICU, intensive care unit; NDE, no de-escalation.
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Moraxella catarrhalis

Table 3.

Primary and Secondary Outcomes

Outcome

Total (n = 1812)

DE (n = 786)

NDE (n = 1026)

P Value

622 (34.3)

275 (35.0)

347 (33.8)

.604
.660

Primary Outcome
Composite treatment failurea
Secondary Outcomes
30-day all-cause mortality

252 (32.1)

319 (31.1)

65 (3.6)

28 (3.6)

37 (3.6)

.960

Readmission for pneumonia within 30 days of hospital discharge

97 (5.4)

37 (4.7)

60 (5.8)

.285

Readmission any within 30 days of hospital discharge

382 (21.1)

162 (20.6)

220 (21.4)

.667

Treatment re-escalation

416 (23.0)

191 (24.3)

225 (21.9)

.234

In-hospital mortality

517 (28.5)

212 (27.0)

305 (29.7)

.198

14-day mortality

407 (22.5)

180 (22.9)

227 (22.1)

.695

Days from index to expirationc

16 [8–58]

15 [7–53]

16 [8–59]

.165

Hospital Length of Stay, Days

21 [13–35]

20 [13–33]

22 [14–36]

.006

12.8 [7.0–22.0]

11.8 [6.9–20.2]

13.6 [7.1–23.9]

.004

10 [5–17]

9 [5–15]

10 [5–18]

.019

Ventilator-free days, percentagee

54.2 [28.6–72.7]

55.0 [30.0–72.7]

53.1 [26.7–72.8]

Antibiotic days from day 0 to 28

10 [6–17]

9 [6–15]

11 [7–18]

<.001

ICU daysd
Days ventilatede

.496

AKI to day 21b
Stage I

546 (35.5)

230 (34.4)

316 (36.4)

.423

Stage II

167 (10.9)

67 (10.0)

100 (11.5)

.352

Stage III

184 (12.0)

70 (10.5)

114 (13.1)

.112

AKI to Day 1 to Day 7b
Stage I

421 (27.4)

169 (25.3)

252 (29.0)

.104

Stage II

118 (7.7)

47 (7.0)

71 (8.2)

.404

Stage III

132 (8.6)

52 (7.8)

80 (9.2)

.321

Stage I

290 (18.9)

108 (16.2)

182 (21.0)

.017

Stage II

89 (5.8)

31 (4.6)

58 (6.7)

.090

Stage III

57 (3.7)

18 (2.7)

39 (4.5)

.065
.065

AKI to Day 8 to Day 14b

AKI to Day 15 to Day 21b
Stage I

151 (9.8)

55 (8.2)

96 (11.1)

Stage II

48 (3.1)

22. (3.3)

26 (3.0)

.739

Stage III

28 (1.8)

10 (1.5)

18 (2.1)

.402
.098

New RRTb

163 (10.6)

61 (9.1)

102 (11.8)

Clostridioides difficile infection index to 90 days

56 (3.0)

17 (2.2)

39 (3.8)

.046

Additional vasopressor started days 4 through 7

202 (11.1)

75 (9.5)

127 (12.4)

.057

Abbreviations: AKI, acute kidney injury; DE, de-escalation; ICU, intensive care unit; NDE, no de-escalation; RRT, renal replacement therapy; SD, standard deviation.
NOTE: Results shown as no. (%) or median [interquartile range] unless otherwise indicated.
a

30-day all-cause mortality or readmission for pneumonia within 30 days index pneumonia date.

b

Of 1372 patients without dialysis on admission or receipt of RRT before day 0: 607 in DE group and 765 in NDE group.

c

Of 857 patients with known expiration dates: 365 in DE and 492 in NDE.

d

Of 1733 patients with any time in the ICU: 762 in DE and 971 in NDE.

e

Of 1403 patients with any time ventilated: 626 in DE and 777 in NDE.

of antimicrobial burden and help identify patients that could be
candidates for stewardship interventions.
Our study has several strengths. This is a large, contemporary cohort, which reflects current clinical practices and provides adequate power to minimize type II error. We screened
patients using strict enrollment criteria for nosocomial pneumonia, notably excluding those who met these criteria too early
in their hospital course. We also used a novel yet simple methodology to define antibiotic DE, which is easily reproducible
and provides a comprehensive picture of the overall antimicrobial pressure on a patient’s normal flora. Finally, we were able to
collect and control for many confounding variables, including
8 • OFID • Ilges et al

immunosuppressive medications, ventilator status by day, and
number of vasopressors by day, utilizing a multivariable timeto-event regression analysis.
Our study also has limitations. First, as a single-center retrospective review, this study is subject to selection bias. Although
our groups were relatively well matched at baseline, there
may have been differences between groups that were unaccounted for, thereby limiting the capacity to determine causality. Furthermore, these results may not be generalizable to
other institutions with different patient populations and/or
practice models. For example, all patients in this cohort were
receiving either anti-MRSA or anti-PSAR antibiotics on day
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571 (31.5)

Readmission for pneumonia within 30 days of day 0

CONCLUSIONS

Overuse of broad-spectrum antimicrobials remains a pressing
public health problem. Although it is known that improper empiric antibiotic coverage is associated with increased mortality
in patients with nosocomial pneumonia, excessive broad-spectrum antibiotic coverage carries risks of its own. Our findings
suggest that antibiotic DE is not associated with composite treatment failure, but instead it may be associated with shorter hospitalizations and reduced rates of C difficile infection. Further
studies are needed to fully understand the utility of spectrum
score-based determinations of antibiotic DE.
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1, which may have made it relatively “easy” to be de-escalate.
Second, using changes in spectrum scores to identify DE may
lack specificity, because the difference in scores between 2 days
can be influenced by minor changes in antibiotic orders (eg,
one-time dose of aminoglycoside on day 1 and not continued
on day 3). We also assessed antibiotic orders, not administrations. Although it is possible that some antibiotic orders were
“counted” despite having never been administered, we considered such events rare enough to have minimal impact on
the results. Furthermore, calculation of the modified ASI was
consistent between treatment groups, and the differences in
the groups remained evident over time as shown in Figure 2.
Third, approximately one third of the patients in this study had
coinfections, which may have impacted the ability to de-escalate; however, groups were well matched at baseline regarding
number and type of coinfections (Supplementary Tables 6 and
7). Fourth, only a subset of vasopressors (norepinephrine, vasopressin, and dobutamine) were included. Fifth, most patients
in this cohort were in the ICU, so results may not be generalizable to nosocomial pneumonia in noncritically ill patients.
Finally, interpretation of chest radiographs and clinical criteria
for establishing a diagnosis of pneumonia were determined by
treating physicians at the time of hospital admission. Although
this could introduce heterogeneity in terms of pneumonia diagnoses, we believe such heterogeneity reflects real-world circumstances and is therefore generalizable to other institutions.

